A phase 2, randomized, dose-finding study of the novel once-weekly human glp-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
That decline shows up as stubborn body fat, poor sleep, slow recovery, and thinning skin
Skin care choices are independent of the medication protocol
KEAP1-independent NRF2 activators Given the complex regulation of the KEAP1-NRF2 system, it is not surprising that new pharmacological strategies are being explored, aimed at inducing NRF2 activity also in a KEAP1-independent manner
These findings represent an important development for cognitive health protection
2019 update to: management of hyperglycaemia in type 2 diabetes, 2018